The earnings call reflects a mixed performance with notable achievements in sales growth and operational efficiency, countered by significant challenges in product lines and lowered guidance due to external and internal factors.

Company Guidance

During Baxter International's second quarter 2025 earnings call, the company provided updated guidance for the remainder of the year. Baxter anticipates full-year sales growth of 6% to 7% on a reported basis and 3% to 4% on an operational basis, incorporating a foreign exchange contribution of approximately 50 basis points. Adjusted earnings per share (EPS) for the full year are expected to be between $2.42 and $2.52, a slight reduction from previous guidance due to factors such as fluid conservation efforts and a voluntary pause in Novum infusion pump shipments. For the third quarter, Baxter projects sales growth of 6% to 7% on a reported basis and adjusted EPS of $0.58 to $0.62. The company is taking a cautious approach, factoring in possible downside risks, including ongoing fluid conservation and the temporary hold on Novum shipments, which could impact operational and financial performance.

Sales and Earnings Growth

Second quarter sales from continuing operations grew 4% on a reported basis and 1% operationally, with adjusted earnings per share from continuing operations increasing 28% over the prior year to $0.59.

Advanced Surgery Growth

Sales in Advanced Surgery totaled $296 million, growing 5% globally, reflecting strong demand for hemostats and sealants.

Care & Connectivity Solutions Growth

Care & Connectivity Solutions sales increased 4% to $474 million, with international sales rising 7% and U.S. sales increasing 3%.

Operational Efficiency

Operating margin improved to 15.1%, reflecting lower SG&A costs and the benefit of TSA income and other reimbursements.

New Leadership

Appointment of Andrew Hider as the new CEO, bringing a strong operational background and a track record of value creation.

Baxter International (BAX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BAX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	0.60 / -	0.49	―	―	―
Jul 31, 2025	2025 (Q2)	0.61 / 0.59	0.68	-13.24% (-0.09)
May 01, 2025	2025 (Q1)	0.48 / 0.55	0.65	-15.38% (-0.10)
Feb 20, 2025	2024 (Q4)	0.53 / 0.58	0.88	-34.09% (-0.30)
Nov 08, 2024	2024 (Q3)	0.78 / 0.49	0.82	-40.24% (-0.33)
Aug 06, 2024	2024 (Q2)	0.66 / 0.68	0.66	3.03% (+0.02)
May 02, 2024	2024 (Q1)	0.61 / 0.65	0.59	10.17% (+0.06)
Feb 08, 2024	2023 (Q4)	0.86 / 0.88	0.88	0.00% (0.00)
Nov 02, 2023	2023 (Q3)	0.67 / 0.82	0.82	0.00% (0.00)
Jul 27, 2023	2023 (Q2)	0.60 / 0.66	0.87	-24.14% (-0.21)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

BAX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	$28.05	$21.76	-22.42%
May 01, 2025	$31.00	$30.50	-1.61%
Feb 20, 2025	$30.50	$33.09	+8.49%
Nov 08, 2024	$35.48	$34.11	-3.86%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.